Ulcerative Colitis study: LY4268989 vs Mirikizumab
Official title LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
ClinicalTrials.gov ID: NCT07186101
What this study is testing
What is LY4268989?
an investigational oral medicine being studied as a potential treatment for ulcerative colitis
Also referred to as MORF-057, zotemtegrast.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether adding LY4268989 to mirikizumab works better and is safe for adults with moderately to severely active ulcerative colitis.
- Who it's for
- You may be able to join if you are an adult with moderately to severely active ulcerative colitis.
- What's involved
- You would receive mirikizumab plus LY4268989 or mirikizumab alone. You will have regular visits and check‑ups during the study.
- Time commitment
- The study lasts about 118 weeks with up to 21 visits, including 104 weeks of treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Have had an established diagnosis of UC of ≥3 months in before baseline, which includes endoscopic evidence of UC and a histopathology report that...
- Have moderately to severely active UC as defined by a mMS of 5 to 9 with an ES ≥2 confirmed by central reader at screening endoscopy and RB ≥1.
- Participants with greater than 8 years of UC symptoms have documented evidence of having had a surveillance colonoscopy within 1 year, or according...
- Are up-to-date on colorectal cancer surveillance per local society guidelines
- Conventional-failed participants: Participants who have had an inadequate response to or a loss of response to or are intolerant to at least 1 of the...
You likely can't join if
- Have a current diagnosis of
- Crohn's disease
- Inflammatory Bowel Disease (IBD) unclassified (formerly known as indeterminate colitis), or
- primary sclerosing cholangitis
- Have had or will need bowel resection or intestinal or intra-abdominal surgery
- Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a...
See the full eligibility criteria
- Have had an established diagnosis of UC of ≥3 months in before baseline, which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC
- Have moderately to severely active UC as defined by a mMS of 5 to 9 with an ES ≥2 confirmed by central reader at screening endoscopy and RB ≥1.
- Participants with greater than 8 years of UC symptoms have documented evidence of having had a surveillance colonoscopy within 1 year, or according to local country or regional medical guidelines, to evaluate for...
- Are up-to-date on colorectal cancer surveillance per local society guidelines
- Conventional-failed participants: Participants who have had an inadequate response to or a loss of response to or are intolerant to at least 1 of the following medications: corticosteroids or immunomodulators (Does not...
- a biologic or biosimilar medication such as anti-tumor necrosis factor (anti-TNF) antibodies or anti-interleukin antibodies (IL-12/23, or IL-23p19), except for
- mirikizumab.
- Janus kinase inhibitors (JAK) such as filgotinib, tofacitinib, or upadacitinib
- sphingosine 1-phosphate receptor 1 inhibitors (S1PR) such as etrasimod or ozanimod
- Have a current diagnosis of
- Crohn's disease
- Inflammatory Bowel Disease (IBD) unclassified (formerly known as indeterminate colitis), or
- primary sclerosing cholangitis
- Have had or will need bowel resection or intestinal or intra-abdominal surgery
- Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic
- Have any adenomatous polyp occurring in areas of the colon not involved by colitis, that has not been removed Note: If such an adenomatous polyp has been completely removed and shows only low-grade dysplasia, this...
- Have a current or recent acute, active infection
The study team makes the final eligibility decision.
Where it is enrolling
- Scottsdale, Arizona, United States
- Anaheim, California, United States
- Lancaster, California, United States
- Los Angeles, California, United States
- Colorado Springs, Colorado, United States
- Hialeah, Florida, United States
- Jacksonville, Florida, United States
- Kissimmee, Florida, United States
- Lakewood Rch, Florida, United States
- Lighthouse PT, Florida, United States
- Margate, Florida, United States
- Orlando, Florida, United States
- Des Plaines, Illinois, United States
- Glenview, Illinois, United States
- Gurnee, Illinois, United States
- New Albany, Indiana, United States
- Louisville, Kentucky, United States
- Boston, Massachusetts, United States
- Clinton Township, Michigan, United States
- Flowood, Mississippi, United States
+ 105 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Scottsdale, Arizona, United States; Anaheim, California, United States; Lancaster, California, United States; Los Angeles, California, United States; Colorado Springs, Colorado, United States; Hialeah, Florida, United States and 119 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.